Dutch life science public–private partnership organization Lygature and Medicines for Malaria Venture (MMV) announced the establishment of a Netherlands-based translational research consortium. This consortium is comprised of the Radboud University of Nijmegen Medical Centre, TropIQ, Pansynt, Mercachem, BPRC, and Pivot Park Oss.
The aim of this program is to develop next-generation medicines to help eradicate malaria. Among a wide range of deliverables, the consortium is expected to deliver the Netherlands’ first antimalarial preclinical drug candidate by 2018.
“One organization alone cannot defeat malaria. Partnerships are the only way forward,” commented Tim Wells, Chief Scientific Officer at MMV.
Frank Leemhuis (Managing Director at Mercachem) says: “It is great to be part of this high-caliber consortium and make a contribution to finding a cure for this disease, which has already affected so many people for such a long time”.